Microfluidics for producing poly (lactic-co-glycolic acid)-based pharmaceutical nanoparticles.

Area of Science:

• Biomaterials Science
• Nanotechnology
• Drug Delivery Systems

Background:

• Poly (lactic-co-glycolic acid) (PLGA) is an FDA-approved biodegradable polymer widely used in drug delivery.
• PLGA-based nanoparticles (NPs) are promising carriers for cancer therapeutics, often formulated with lipids or amphiphiles.
• Conventional methods for NP production are time-consuming and face challenges in reproducibility.

Purpose of the Study:

• To review the advantages of microfluidic chips for producing PLGA-based nanocomplexes.
• To highlight the efficiency and reproducibility of microfluidics in nanoparticle synthesis.
• To discuss the scalability of microfluidic methods for clinical and industrial applications.

Main Methods:

• Utilizing microfluidic chips for controlled synthesis of nanoparticles.
• Varying precursor materials and flow rates to generate diverse nanoparticle libraries.
• Precise control over process parameters to ensure batch-to-batch consistency.

Main Results:

• Microfluidic chips significantly reduce the time required for screening optimal nanoparticle formulations.
• High batch-to-batch reproducibility is achieved, crucial for clinical translation.
• PLGA-based NPs produced via microfluidics demonstrate potential as effective drug carriers.

Conclusions:

• Microfluidic technology offers a superior approach for producing functional PLGA-based nanoparticles for drug delivery.
• The method facilitates rapid screening and ensures reproducibility, accelerating the development of nanomedicines.
• Microfluidic systems are scalable for both preclinical studies and large-scale industrial production.